|
GENOUS™ SUCCESS STORY
Clinical trial successful for a 62-year-old patient with cervical cancer
THE CHALLENGE
After her first-line treatment failed, the outlook was grim. The challenge was finding a treatment that could effectively target the cancer’s genetic drivers and offer her a chance at extended survival. She needed something more than standard care—she needed a breakthrough.
In 2013, a 62-year-old woman was diagnosed with large cell neuroendocrine cervical cancer. The cancer was aggressive, spreading to her liver, lungs, and bones, despite first-line treatment with carboplatin and etoposide
PRECISION CANCER SOLUTIONS
Her treating team conducted comprehensive genomic profiling. This analysis revealed multiple genetic mutations, including a BRCA2 variant initially classified as a VUS. With the insights from the Genomate Report, the molecular tumor board experts reinterpreted the BRCA2 mutation, identifying it as functionally significant. They recommended the patient’s participation in a clinical trial for Olaparib, a PARP inhibitor known to be effective in BRCA-mutated cancers.
THE RIGHT DRUG. THE FIRST TIME. EVERYTIME
Patients responded positively to Olaparib in clinical trials, remaining stable for at least one year. Participation in the trial significantly prolonged survival and improved quality of life for patients.
For the treatment team, this means:
Higher success rate
Make decisions faster
Limit guesswork and side effects
Give patients the best treatment opportunities
OUTCOMES AND IMPACT OF TARGETED THERAPY